Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma - Test2 - elhamkhani - TriplyDB

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

http://www.wikidata.org/entity/Q24605861

about

What is the functional role of the thalidomide binding protein cereblon?Monoclonal antibodies targeting CD38 in hematological malignancies and beyond The Role of Immunotherapy in Multiple Myeloma Potential role of daratumumab in the treatment of multiple myeloma Current and emerging treatment options for patients with relapsed myeloma Pomalidomide for the treatment of multiple myeloma Use of lenalidomide in the management of relapsed or refractory multiple myeloma: expert recommendations in Korea Multiple myeloma: 2014 Update on diagnosis, risk-stratification, and management Targeted therapy for HM1.24 (CD317) on multiple myeloma cells Development of Novel Immunotherapies for Multiple Myeloma Novel therapeutic strategies for multiple myeloma Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function What does it take to synergistically combine sub-potent natural products into drug-level potent combinations?Combination with a defucosylated anti-HM1.24 monoclonal antibody plus lenalidomide induces marked ADCC against myeloma cells and their progenitors Renal Toxicities of Novel Agents Used for Treatment of Multiple Myeloma."Real-world" data on the efficacy and safety of lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma who were treated according to the standard clinical practice: a study of the Greek Myeloma Study Group.Pomalidomide for the treatment of relapsed-refractory multiple myeloma: a review of biological and clinical data.Lenalidomide for the treatment of relapsed and refractory multiple myeloma.Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma Recent advances in antimultiple myeloma drug development.A multicenter phase 2 study of pomalidomide plus dexamethasone in patients with relapsed and refractory multiple myeloma: the Japanese MM-011 trial Managing patients with myelofibrosis and low platelet counts.Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma Efficacy and Safety of Lenalidomide for Treatment of Low-/Intermediate-1-Risk Myelodysplastic Syndromes with or without 5q Deletion: A Systematic Review and Meta-Analysis Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis.Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed, Lenalidomide Refractory Multiple Myeloma.Recovery of polyclonal immunoglobulins one year after autologous stem cell transplantation as a long-term predictor marker of progression and survival in multiple myeloma Expression of cereblon protein assessed by immunohistochemicalstaining in myeloma cells is associated with superior response of thalidomide- and lenalidomide-based treatment, but not bortezomib-based treatment, in patients with multiple myeloma.Internal ribosome entry site of bFGF is the target of thalidomide for IMiDs development in multiple myeloma.Novel agents for the treatment of multiple myeloma: proteasome inhibitors and immunomodulatory agents Bone disease in multiple myeloma: pathophysiology and management.Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide.A critical review of the molecular pathophysiology of lenalidomide sensitivity in 5q - myelodysplastic syndromes.Macrophages in multiple myeloma: emerging concepts and therapeutic implications.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Increased T regulatory cells are associated with adverse clinical features and predict progression in multiple myeloma.Ribosomopathies: mechanisms of disease.Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs Evidence of a role for activation of Wnt/beta-catenin signaling in the resistance of plasma cells to lenalidomide.

P2860

Q24635072-246862B8-C4FA-470A-B203-1AFB3696B447 Q26766718-62349312-0797-4002-BB52-C56C04D52132 Q26771144-8C47B731-B4B9-444B-885D-912DBF6DE2B2 Q26824157-D7DA4C97-AAA4-466D-B6D5-D5E1903F5365 Q26830878-1449A3AC-BA56-4C3C-A6B0-E7C5DADCD123 Q26859133-3DA55CC8-0D47-477D-B01A-6A11B779B47B Q26992002-6E816D32-C18A-4959-820E-E2F6DB45875C Q26998884-87D79428-15DB-4FF2-BDA7-EAEE864025D6 Q27026161-50D74B5D-B37F-4AA1-A964-86B1738AF889 Q28066890-C1C5B6CE-3AB6-452A-A85F-899D0C1BE440 Q28081590-F16BDF70-266B-4AC3-8820-0E1563B3CFCA Q28383385-BA6577F9-58E7-43AF-99A6-AF1ACFF48FCC Q28485360-390F32ED-7981-4143-9294-F2A32AC012B7 Q28537997-44EE3100-2799-43A8-835E-0130952FE9CF Q30275870-99E1EDDF-30D2-4018-83E9-341AE330AE06 Q30657752-753545BA-32B1-4044-9608-95591061608D Q30802505-D893F9A8-9F58-4435-A3DD-0807AD7CEA9C Q33403183-CB193522-2945-4B1C-A5B7-1C55B78507D2 Q33413142-A936CA3E-FE93-4D97-96F4-166128DD371B Q33416297-E8C38B52-A67C-471F-B405-A7DF68A13BD9 Q33431621-D6D6E4A9-3AFE-4AB5-B9DE-6ADF0E3F1B71 Q33432406-3C9111CD-9D8E-458D-97C0-2C93DDCA8BBA Q33432492-BA49ED6D-40AF-4EAA-AEFD-0C67179E2DF0 Q33436627-AB683D5D-6CC6-4B14-AA68-6E69F633E462 Q33441845-8EE5506F-6749-4A46-8891-ECD7F5496FAB Q33442923-B0B37EAD-EC5E-4A16-B556-F31B5676A833 Q33443411-3B1D7E58-299E-4F46-B9E6-CCDBAFEFEFE6 Q33816012-400D5769-13C1-444C-B94C-CADB6B72BB29 Q33846806-A92EC842-F4B0-4B86-BC52-771B6A0480A5 Q33880085-052B0B7A-F816-486B-9E7C-017D1307F318 Q33886073-02F62AEA-705A-4BB8-9789-9AE02EAE2BDD Q34045789-8D980A89-7B97-4F7F-858F-9D702D35478E Q34210005-117225AE-6942-494C-AF66-EB47599A2079 Q34220013-55524B75-A8D0-4794-AE08-F165D7B7B26C Q34329242-B37D2B26-B957-4F1E-AFFB-939F24BF125B Q34380489-11ACB3A6-5431-41BE-A0A6-563018F2B070 Q34447864-B98388DB-343D-46DB-8DE5-A65A0E7A7FBC Q34454066-CBC3EBC0-1DC3-4868-B3FA-6C7BE2E30EC9 Q34661167-F063577D-4DFB-461F-BAD4-36B5DECAA772 Q34719436-6F695579-6F0A-4668-BB39-97EAFDCFECFF

P2860

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

http://www.wikidata.org/entity/Q24605861

description

2010 nî lūn-bûn

@nan

2010 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@ast

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@en

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@nl

type

label

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@ast

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@en

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@nl

prefLabel

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@ast

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@en

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@nl

P1433

Q24605861-4A3B0EB0-1E75-4BD1-BE9F-A9ED7D96FCB5

P1476

Q24605861-2722A183-EA77-4C38-875C-52B582E5395D

P2093

Q24605861-346B55FD-236E-49A0-9838-AED92F378189

Q24605861-6209AE6B-01AE-46F1-A3C1-7A5C08A3FEFD

Q24605861-928340EB-1FAF-400A-A487-C3BDE8D7DB85

Q24605861-D784E78C-EA68-490E-9998-78F472CDEA64

P2860

Q24605861-02343A76-0A42-46B7-A513-7586E93A90D1

Q24605861-05E8CEA8-8189-40CE-89AC-FC62F255B023

Q24605861-0A5C52BB-95CC-472B-ABAE-53DB5E729935

Q24605861-0AEFF24B-EE06-44A1-8954-9707B41FA527

Q24605861-1376E677-7E50-4A17-AB8C-A3E02B06163C

Q24605861-157D6705-FB3F-40F9-80A7-BAB1244E3C8E

Q24605861-285EEEC4-3A67-4606-BD6D-F2A757D1CCE7

Q24605861-2B8ACDA2-DD13-49EC-816C-F86A2DB4C53F

Q24605861-369E538B-43C7-4224-A9B9-7723E62C68C9

Q24605861-37358311-6938-4E3B-9061-F0B008DD2C0C

P2888

Q24605861-336630C3-3AD8-4F9C-87E2-488DFF9E318F

P304

Q24605861-16CD7CF9-D63C-436C-A56B-A08DFDEF661F

P31

Q24605861-0708236C-C36E-4D65-9340-EB5BD7160DA9

P3181

Q24605861-7138CCE4-BA87-4AFC-9A33-2783328488E6

P356

Q24605861-1380BA14-2E53-4478-AA4D-0177637B7FE5

P407

Q24605861-6469028B-B4AA-4EE3-BF6E-D6B01ADF9BB8

P433

Q24605861-A0BCD99D-D161-4763-BEE3-EFF1514FEAD4

P478

Q24605861-F4C921F6-62A6-4E1A-9911-3B4AA2629A60

P50

Q24605861-6507044E-691E-4515-902D-DE0D5B2A77B2

Q24605861-7914AAB5-6E44-4096-A371-D856AE09D667

Q24605861-C5BE4F8E-CDFE-435F-9D75-0BF298C64274

P577

Q24605861-96394882-F7AE-4BEE-B493-216B927B2688

P6179

Q24605861-EC91EEDB-F49C-406D-8EC3-E8AD94FE4239

P698

Q24605861-717C05C1-88AF-4452-8236-2B15D4A6C084

P932

Q24605861-BA96CB74-7F1B-4004-A34F-DDCAD54AA986

P3181

P356

P1433

P1476

Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma

@en

P2093

A K Stewart

http://www.w3.org/2001/XMLSchema#string

D Ritchie

http://www.w3.org/2001/XMLSchema#string

H M Prince

http://www.w3.org/2001/XMLSchema#string

H Quach

http://www.w3.org/2001/XMLSchema#string

P2860

Thalidomide and thalidomide analogues for maintenance of remission in Crohn's disease

Thalidomide is an inhibitor of angiogenesis

Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells

Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

Immunosuppressive networks in the tumour environment and their therapeutic relevance

Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction.

Immunomodulation by thalidomide and thalidomide analogues

Amino-substituted thalidomide analogs: potent inhibitors of TNF-alpha production.

P2888

P304

22-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2112982

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/LEU.2009.236

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

24

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-11-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1026282357

http://www.w3.org/2001/XMLSchema#string

P698

19907437

http://www.w3.org/2001/XMLSchema#string

P932

3922408

http://www.w3.org/2001/XMLSchema#string